Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus

Nanmoku, Koji; Shinzato, Takahiro; Kubo, Taro; Shimizu, Toshihiro; Kimura, Tomonori; Yamada, Takashi

doi:10.1016/j.transproceed.2018.01.028

Cited by 4 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We could not find any published reports on the effects of reducing the dose of tacrolimus, CsA or corticosteroids; replacing tacrolimus or CsA with MMF or azathioprine; reducing the dose or discontinuing a mTORi on PTDM. One small retrospective, non-controlled trial showed that switching patients with PTDM from methylprednisolone to everolimus on top of tacrolimus and MMF did not worsen HbA1c over time [45]. An extension of this trial showed a significant decrease in HbA1c levels 9 months after conversion from methylprednisolone to everolimus [46].…”

Section: Immunosuppressive Regimenmentioning

confidence: 92%

Management of metabolic alterations in adult kidney transplant recipients: A joint position statement of the Italian Society of Nephrology (SIN), the Italian Society for Organ Transplantation (SITO) and the Italian Diabetes Society (SID)

Conte

Maggiore

Cappelli

et al. 2020

Nutrition, Metabolism and Cardiovascular Diseases

View full text Add to dashboard Cite

Chronic metabolic alterations such as post-transplant diabetes mellitus (PTDM), dyslipidaemias and overweight/obesity significantly impact on kidney transplant (KT) outcomes. This joint position statement is based on the evidence on the management of metabolic alterations in KT recipients (KTRs) published after the release of the 2009 KDIGO clinical practice guideline for the care of KTRs. Members of the Italian Society of Nephrology (SIN), the Italian Society for Organ Transplantation (SITO) and the Italian Diabetes Society (SID) selected to represent professionals involved in the management of KTRs undertook a systematic review of the published evidence for the management of PTDM, dyslipidaemias and obesity in this setting. The aim of this work is to provide an updated review of the evidence on the prevention, diagnosis and treatment of metabolic alterations in KTRs, in order to support physicians, patients and the Healthcare System in the decision-making process when choosing among the various available options.

show abstract

Section: Immunosuppressive Regimenmentioning

confidence: 92%

Management of metabolic alterations in adult kidney transplant recipients: A joint position statement of the Italian Society of Nephrology (SIN), the Italian Society for Organ Transplantation (SITO) and the Italian Diabetes Society (SID)

Conte

Maggiore

Cappelli

et al. 2020

Nutrition, Metabolism and Cardiovascular Diseases

View full text Add to dashboard Cite

show abstract

Advancement in preoperative desensitization therapy for ABO incompatible kidney transplantation recipients

Man

Gui

et al. 2023

Transplant Immunology

View full text Add to dashboard Cite

Rapamycin for longevity: opinion article

Blagosklonny

2019

Aging

147

View full text Add to dashboard Cite

From the dawn of civilization, humanity has dreamed of immortality. So why didn’t the discovery of the anti-aging properties of mTOR inhibitors change the world forever? I will discuss several reasons, including fear of the actual and fictional side effects of rapamycin, everolimus and other clinically-approved drugs, arguing that no real side effects preclude their use as anti-aging drugs today. Furthermore, the alternative to the reversible (and avoidable) side effects of rapamycin/everolimus are the irreversible (and inevitable) effects of aging: cancer, stroke, infarction, blindness and premature death. I will also discuss why it is more dangerous not to use anti-aging drugs than to use them and how rapamycin-based drug combinations have already been implemented for potential life extension in humans. If you read this article from the very beginning to its end, you may realize that the time is now.

show abstract

Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus

Cited by 4 publications

References 23 publications

Management of metabolic alterations in adult kidney transplant recipients: A joint position statement of the Italian Society of Nephrology (SIN), the Italian Society for Organ Transplantation (SITO) and the Italian Diabetes Society (SID)

Management of metabolic alterations in adult kidney transplant recipients: A joint position statement of the Italian Society of Nephrology (SIN), the Italian Society for Organ Transplantation (SITO) and the Italian Diabetes Society (SID)

Advancement in preoperative desensitization therapy for ABO incompatible kidney transplantation recipients

Rapamycin for longevity: opinion article

Contact Info

Product

Resources

About